User Blocked After Repeated Policy Violations

When Lisa Spain founded Rexana’s Foundation in 2006 after her close friend died from lung cancer just two months after diagnosis, the therapeutic options were limited and the idea of a daily pill replacing chemotherapy seemed far‑off.

Targeted therapies move into a new era

Today, a generation of targeted drugs offers patients the chance to control their disease for years. Dr. Bruna Pellini, chief of thoracic medical oncology at Baptist Health Herbert Wertheim Cancer Institute, describes the shift as moving from a single option in early training to at least four, sometimes five, agents for mutations such as ROS1 fusions. “I remember when I was in training, we did not have many options. We had one option,” she said, noting the surge in available treatments.

One recent approval, according to the specialist, has allowed patients to stay on the same medication for more than four years—a duration unheard of with older drugs. Dr. Eric Singhi likens these advances to newer smartphone models, where better cameras and longer battery life translate to extended disease control and improved quality of life for patients.

Survival data reflects longer benefit

Clinical trials of the newest agents often list median overall survival as “not yet reached.” In plain language, this means that more than half of participants were still alive when the study closed, indicating that the therapies are extending life beyond the original expectations of the trial design.

For Leah Phillips, who has been on a targeted therapy for six and a half years—far longer than the 18‑ to 24‑month window originally projected—the progress is personal. “Here I sit on this drug for six‑and‑a‑half years, that was only supposed to work 18 months to two to three years at best,” she explained, crediting her oncologist’s advice to focus on daily goals while letting researchers work toward turning cancer into a chronic condition.

Phillips also stresses the importance of staying alert to clinical trials that match a patient’s specific mutation. “Stay aware of what’s out there,” she urged, adding that a thoracic oncologist can help guide emerging options.

Across the board, patient‑advocacy groups are emerging as trusted sources for digestible updates.

Panelists agreed that the human element underlies every statistic. Ongoing research funding, thorough genetic testing, and specialist involvement aim to give more patients the chance to say, “I didn’t think I’d be sitting here. And I am.”